Asymmetric synthesis of an MMP-3 inhibitor incorporating a 2-alkyl succinate motif
An efficient and practical synthesis is presented of the pharmaceutically active MMP-3 inhibitor UK-370,106 (1) via an olefination/catalytic asymmetric hydrogenation sequence. Commercially available 5-bromo-2-iodotoluene was converted in two steps to the
Ashcroft, Christopher P.,Challenger, Stephen,Derrick, Andrew M.,Storey, Richard,Thomson, Nicholas M.
p. 362 - 368
(2013/09/06)
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers
The pathology of chronic dermal ulcers is characterized by excessive proteolytic activity which degrades extracellular matrix (required for cell migration) and growth factors and their receptors. The overexpression of MMP-3 (stromelysin-1) and MMP-13 (col
Fray, M. Jonathan,Dickinson, Roger P.,Huggins, John P.,Occleston, Nicholas L.
p. 3514 - 3525
(2007/10/03)
Matrix metalloprotease inhibitors
Compounds of formula (I): or pharmaceutically acceptable salts thereof, or solvates of either entity, wherein the substituents have the values described herein, are useful as matrix metalloprotease (MMP) inhibitors
-
(2012/04/23)
More Articles about upstream products of 230961-21-4
Get Best Price for230961-21-4(R)-3-((S)-1-((S)-2-methoxy-1-phenylethylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamoyl)-6-(2-methylbiphenyl-4-yl)hexanoic acid